# To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus

> **NCT05814393** · PHASE3 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 200 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Treatment Period(JW0201)
- **DRUG:** Treatment Period(Placebo)
- **DRUG:** Extension Period(JW0201)

## Key facts

- **NCT ID:** NCT05814393
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-03
- **Primary completion:** 2024-05-14
- **Final completion:** 2024-11-20
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05814393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05814393, "To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05814393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*